# Novo Nordisk Moat

Status: published. Policy: company-analysis-1.

Novo Nordisk retains a narrow, eroding moat from patented, approved medicines with demonstrated demand and successful product extensions. Wegovy pill uptake and broader launches strengthen evidence of commercial renewal, but 2025 share losses, continued realized price declines and 2026 gross-margin compression show material erosion. Manufacturing capability supports delivery without establishing a relative cost advantage. Remaining patents support finite protection, not guaranteed durability or strong pricing power.

## intangible_assets

Patents and marketed therapeutic franchises provide a current barrier to direct replication. Multi-year Wegovy growth, prescription uptake for its oral formulation and approvals for additional formulations demonstrate commercialization beyond a prospective pipeline.

Durability: The 2025 patent table lists principal semaglutide products through 2032 in the US and 2031 in Japan and Europe, but 2026 in China. Other patents may extend protection, although their effectiveness is unproven here. Renewal is demonstrated commercially, but long-term resistance to substitution remains mixed.

Risks: Actual GLP-1 volume-share losses, lower realized prices, generic patent challenges and geographically uneven exclusivity weaken protection. Pipeline failures and impairments constrain confidence in replacement products. Strong prescription starts do not establish patient persistence or superior economics.

Invalidation: The narrow-moat thesis would fail if generic entry or competing treatments caused sustained declines in underlying franchise volumes and sales despite new formulations, or if successful patent challenges removed protection in major markets before replacement products established meaningful demand. Persistent price and gross-profit deterioration despite volume growth would further invalidate economic protection.

Competitors: Cipla
- [https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm](https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm) · 2026-02-04
- [https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/nvo-20241231.htm](https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/nvo-20241231.htm) · 2025-02-05
- [https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/nvo-20231231.htm](https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/nvo-20231231.htm) · 2024-01-31
- [https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm](https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm) · 2026-02-04
- [https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/nvo-20241231_d2.htm](https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/nvo-20241231_d2.htm) · 2025-02-05
- [https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/nvo-20231231_d2.htm](https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/nvo-20231231_d2.htm) · 2024-01-31
- [https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm) · 2026-08-04
- [https://www.sec.gov/Archives/edgar/data/353278/000035327826000018/caq12026.htm](https://www.sec.gov/Archives/edgar/data/353278/000035327826000018/caq12026.htm) · 2026-05-06

[JSON](https://beanvest.com/stock/nvo/moat.json)